Effect of COVID 19 on Parkinson's disease (PD) clinical features: A community based case control study

The primary objective of the study was to investigate the effects of COVID-19 on motor and nonmotor symptoms in a community-based Parkinson Disease cohort. In addition, we explored whether older age and longer disease duration represented risk factors for developing symptomatic COVID-19. Materials and method: In the present observational, community-based, case-control study, we investigated demographic and clinical features in a cohort of patients with idiopathic PD and COVID-19 as compared to control PD subjects between the pre-outbreak period in Italy (January 01st, 2020) and the end of lockdown restrictions (May 4th, 2020). A 3-month period was chosen to minimize the effect of PD progression on the change in clinical features and the recall bias. Diagnosis of COVID-19 was performed according to clinical and laboratory criteria for probable and confirmed cases, released by the World Health Organization criteria on March 20th, 2020. PD Patients may experience substantial worsening of motor and nonmotor symptoms during mild-to-moderate COVID-19 illness, independently of age and disease duration. Clinicians should take pharmacokinetic changes into consideration before adjusting therapy regimen (e.g., management of dehydration secondary to fever, diarrhoea, anorexia with reduced water intake). Although we speculate that subacute clinical changes in PD associated to nonsevere COVID-19 illness are likely caused by systemic inflammatory response rather than a direct invasion of the central nervous system, further studies in larger PD populations are warranted to clarify the cause-effect relationship among clinical changes and the severity of COVID-19 illness, cytokine levels and virus detection in the cerebrospinal fluid. To read more- https://onlinelibrary.wiley.com/doi/epdf/10.1002/mds.28170


Useful share . Nice to learn.
Much informative